Co-delivery of doxorubicin-dihydroartemisinin prodrug/TEPP-46 nano-liposomes for improving antitumor and decreasing cardiotoxicity in B16-F10 tumor-bearing mice
Source abstract
Abstract
In order to reduce the cardiotoxicity of doxorubicin (DOX) and improve its antitumor effect, dihydroartemisinin (DHA) and DOX prodrug (DOX-S-DHA) synthesized via a single sulfur bond was used with TEPP-46 to prepare nano-liposomes (DOX-S-DHA@TEPP-46 Lips). In which, TEPP-46 was expected to exert p53 bidirectional regulation to promote the synergistic antitumor effect of DOX and DHA while reducing cardiotoxicity. DOX-S-DHA@TEPP-46 Lips exhibited uniform particle size, good stability, and excellent redox-responsive activity. DOX-S-DHA@TEPP-46 Lips could significantly inhibit the proliferation of tumor cells, but had less cytotoxicity on normal cells. The presence of TEPP-46 increased the content of p53 protein, which further induced tumor cell apoptosis. DOX-S-DHA@TEPP-46 Lips had satisfactory long circulation to enhance the antitumor efficacy and reversed the cardiotoxicity of DOX in B16-F10 tumor-bearing mice. In conclusion, DOX-S-DHA@TEPP-46 Lips provides a new insight on creating sophisticated redox-sensitive nano-liposomes for cancer therapy as well as the decreased cardiotoxicity of DOX.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (38)
Show source-provided references
1. Localized therapy using anti-PD-L1 anchored and NIR-responsive hollow gold nanoshell (HGNS) loaded with doxorubicin (DOX) for the treatment of locally advanced melanoma10.1016/j.nano.2020.102349 ↗
2. PCL/gelatin nanofibers embedded with doxorubicin-loaded mesoporous silica nanoparticles/silver nanoparticles as an antibacterial and anti-melanoma cancer10.1016/j.ijpharm.2023.123162 ↗
3. Homotypic targeted nanoplatform enable efficient chemoimmunotherapy and reduced DOX cardiotoxicity in chemoresistant cancer via TGF-β1 blockade10.1016/j.jconrel.2023.07.063 ↗
4. All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy
5. Co-delivery of DOX and PDTC by pH-sensitive nanoparticles to overcome multidrug resistance in breast cancer10.1016/j.colsurfb.2019.05.042 ↗
6. Co-delivery nanoparticles of doxorubicin and chloroquine for improving the anti-cancer effect in vitro10.1088/1361-6528/aaf51b ↗
7. Platelet-armored nanoplatform to harmonize janus-faced IFN-γ against tumor recurrence and metastasis10.1016/j.jconrel.2021.08.020 ↗
8. An injectable hydrogel using an immunomodulating gelator for amplified tumor immunotherapy by blocking the arginase pathway10.1016/j.actbio.2021.01.041 ↗
9. Dihydroartemisinin inhibits melanoma migration and metastasis by affecting angiogenesis10.1002/ptr.8065 ↗
10. Susceptibility of cervical cancer to dihydroartemisinin-induced ferritinophagy-dependent ferroptosis10.3389/fmolb.2023.1156062 ↗
11. Dihydroartemisinin triggers ferroptosis in primary liver cancer cells by promoting and unfolded protein response‑induced upregulation of CHAC1 expression10.3892/or.2021.8191 ↗
12. Dysregulation of Iron Metabolism in Cholangiocarcinoma Stem-like Cells10.1038/s41598-017-17804-1 ↗
13. Construction of reduction-sensitive heterodimer prodrugs of doxorubicin and dihydroartemisinin self-assembled nanoparticles with antitumor activity10.1016/j.colsurfb.2022.112614 ↗
14. Engineering tumor-specific catalytic nanosystem for NIR-II photothermal-augmented and synergistic starvation/chemodynamic nanotherapy10.1186/s40824-022-00317-y ↗
15. Progress in dual-responsive nanocarriers based on acid sensitivity for anticancer drug]
16. Resveratrol reduces ROS-induced ferroptosis by activating SIRT3 and compensating the GSH/GPX4 pathway10.1186/s10020-023-00730-6 ↗
17. The multiple mechanisms that regulate p53 activity and cell fate10.1038/s41580-019-0110-x ↗
18. p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing Act10.3390/nu15102259 ↗
19. PK-M2-mediated metabolic changes in breast cancer cells induced by ionizing radiation10.1007/s10549-019-05376-9 ↗
20. Pyruvate Kinase M2 Activates mTORC1 by Phosphorylating AKT1S1
21. TSP50 promotes the Warburg effect and hepatocyte proliferation via regulating PKM2 acetylation10.1038/s41419-021-03782-w ↗
22. Transcriptomic signatures responding to PKM2 activator TEPP-46 in the hyperglycemic human renal proximal epithelial tubular cells
23. Tissue-specific regulation of p53 by PKM2 is redox dependent and provides a therapeutic target for anthracycline-induced cardiotoxicity10.1126/scitranslmed.aau8866 ↗
24. Oxidative Stress and Pyroptosis in Doxorubicin-Induced Heart Failure and Atrial Fibrillation10.1155/2023/4938287 ↗
25. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
26. Blood circulation stable doxorubicin prodrug nanoparticles containing hydrazone and thioketal moieties for antitumor chemotherapy10.1016/j.colsurfb.2021.111632 ↗
27. Dextran-doxorubicin prodrug nanoparticles conjugated with CD147 monoclonal antibody for targeted drug delivery in hepatoma therapy10.1016/j.colsurfb.2023.113400 ↗
28. Tumor-targeted and stimulus-responsive polymeric prodrug nanoparticles to enhance the anticancer therapeutic efficacy of doxorubicin10.1016/j.jconrel.2024.03.046 ↗
29. Design of red blood cell membrane-cloaked dihydroartemisinin nanoparticles with enhanced antimalarial efficacy10.1016/j.ijpharm.2022.121665 ↗
30. CXCL10-coronated thermosensitive “stealth” liposomes for sequential chemoimmunotherapy in melanoma10.1016/j.nano.2022.102634 ↗
31. TMZ magnetic temperature-sensitive liposomes-mediated magnetothermal chemotherapy induces pyroptosis in glioblastoma10.1016/j.nano.2022.102554 ↗
32. Overcoming the blood–brain barrier by using a multistage exosome delivery system to inhibit central nervous system lymphoma10.1016/j.nano.2022.102523 ↗
33. Novel greenly synthesized titanium dioxide nanoparticles compared to liposomes in drug delivery: in vivo investigation on Ehrlich solid tumor model10.1016/j.heliyon.2021.e07370 ↗
34. Halloysite Clay Nanotubes for Resveratrol Delivery to Cancer Cells10.1002/mabi.201200121 ↗
35. In Vitro Cell Toxicity and Intracellular Uptake of Doxorubicin Exposed as a Solution or Liposomes: Implications for Treatment of Hepatocellular Carcinoma10.3390/cells10071717 ↗
36. In-vitro and in-vivo evaluation and anti-colitis activity of esculetin-loaded nanostructured lipid carrier decorated with DSPE-MPEG200010.1080/02652048.2023.2215345 ↗
37. Impact of the amount of PEG on prodrug nanoassemblies for efficient cancer therapy10.1016/j.ajps.2022.02.002 ↗
38. Preparation and characterization of nanoliposomal bortezomib formulations and evaluation of their anti-cancer efficacy in mice bearing C26 colon carcinoma and B16F0 melanoma10.1016/j.nano.2019.04.016 ↗